Mizuho Maintains Buy on Inspire Medical Systems, Raises Price Target to $250
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Anthony Petrone has maintained a Buy rating on Inspire Medical Systems (NYSE:INSP) and increased the price target from $225 to $250.
February 07, 2024 | 1:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mizuho has reaffirmed its Buy rating on Inspire Medical Systems and raised the price target from $225 to $250.
The increase in price target by a reputable analyst like Anthony Petrone from Mizuho is a strong positive signal for investors, indicating a bullish outlook on the stock. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100